Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy

IMPORTANCE: Although PCSK9 inhibitors (PCSK9i) were approved in 2015, their high cost has led to strict prior authorization practices and high copays, and use of PSCK9i in clinical practice has been low. OBJECTIVE: To evaluate patient access to PCSK9i among those prescribed therapy. DESIGN, SETTING,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Navar, Ann Marie, Taylor, Benjamin, Mulder, Hillary, Fievitz, Eugene, Monda, Keri L., Fievitz, Anna, Maya, Juan F., López, J. Antonio G., Peterson, Eric D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2017
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5963012/
https://ncbi.nlm.nih.gov/pubmed/28973087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2017.3451
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados